GlassScriptPhysician profile
Brooke A Cast
NPI 1386663722
$3,052.44
in general payments reported to CMS, 2019-2025
27 companies · $1,381 in 2025
The $1,381 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $5.73 · 2023: $179 · 2024: $1,487 · 2025: $1,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,935 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,934.88 |
| Education | $111.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $852.40 | 2023-2025 | |
| Janssen Biotech, INC. | $451.73 | 2023-2025 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $367.92 | 2023-2025 | Epclusa |
| Takeda Pharmaceuticals U.S.A., INC. | $249.53 | 2024-2025 | Entyvio, Eohilia |
| Lilly USA, LLC | $248.82 | 2023-2025 | Omvoh |
| Madrigal Pharmaceuticals | $214.46 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $137.46 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $98.08 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $66.96 | 2025 | Voquezna |
| Argenx US, INC. | $46.61 | 2024-2025 | Vyvgart Hytrulo |
| Bayer Healthcare Pharmaceuticals INC. | $26.88 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.74 | 2025 | Ofev |
| Genzyme Corporation | $22.71 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.63 | 2022-2024 | Lifevest |
| Qol Medical, LLC | $20.61 | 2024 | Sucraid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $19.72 | 2025 | |
| Fresenius USA Marketing, INC. | $18.72 | 2025 | Velphoro |
| Celgene Corporation | $18.42 | 2024 | Zeposia |
| Bard Peripheral Vascular, INC. | $18.18 | 2024 | Rotarexs 6 F X 135 Cm |
| Solventum Corporation | $18.01 | 2025 | V.A.C.Ulta, V.A.C. Veraflo, Prevena |
| Csl Behring | $16.78 | 2023 | Hizentra |
| Astrazeneca Pharmaceuticals LP | $16.43 | 2025 | Fasenra |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Vifor Pharma, INC. | $15.62 | 2025 | Veltassa |
| Intercept Pharmaceuticals, INC. | $14.97 | 2025 | |
| Ardelyx, INC. | $13.86 | 2024 | Ibsrela |
| Neurelis, INC. | $13.08 | 2024 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Cast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.